Elevance Health, Inc.
ELV
$394.07
+0.35%
Elevance Health, Inc. is a leading U.S. health insurer providing medical benefits to 45 million members through employer, individual, and government-sponsored plans, operating within the Medical - Healthcare Plans industry. The company's distinct competitive identity stems from its position as the largest single provider of Blue Cross Blue Shield branded coverage, holding the license in 14 states, and its expansion into pharmacy benefit management and healthcare services through strategic acquisitions. The current investor narrative is dominated by the managed care sector's reaction to regulatory updates on Medicare Advantage payments, with recent news highlighting a larger-than-expected 2027 payment increase from CMS, which has boosted revenue visibility and sector-wide sentiment, placing Elevance at the center of debates on government reimbursement trends and their impact on future profitability.…
ELV
Elevance Health, Inc.
$394.07
ELV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $512.29 and implied upside of +30.0% versus the current price.
Average Target
$512.29
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$315 - $512
Analyst target range
Analyst coverage for ELV appears limited with only three analysts providing estimates, which is unusually low for a company of its market cap ($77.8 billion) and suggests it may be under-followed relative to peers, potentially leading to less efficient price discovery. The consensus sentiment, inferred from recent institutional ratings, is overwhelmingly bullish; firms including JP Morgan, Wells Fargo, Barclays, and Guggenheim have all reiterated Overweight or Buy ratings in early 2026, indicating strong institutional conviction following the stock's volatility and the CMS payment update news. A specific average target price and implied upside cannot be calculated from the provided data, as only EPS and revenue estimates are given, not price targets; however, the high degree of recent reaffirmations and upgrades (e.g., Wolfe Research moving to Outperform from Peer Perform) suggests analysts see a favorable risk/reward profile at current levels, with the wide estimated EPS range for the next period ($45.20 to $48.43) pointing to some underlying uncertainty in earnings projections.
Bulls vs Bears: ELV Investment Factors
The bull case, currently supported by stronger evidence, hinges on a powerful technical rebound fueled by a concrete regulatory catalyst (CMS payment boost) and deeply discounted valuation. The bear case centers on legitimate concerns about extreme quarterly earnings volatility and the structural risks of government-dependent revenues. The single most important tension in the investment debate is whether the severe Q4 2025 margin compression was a one-time anomaly or a symptom of deeper, persistent profitability challenges. The resolution of this question—through subsequent quarterly earnings—will determine if the current low multiples represent a value trap or a compelling entry point.
Bullish
- Strong Technical Recovery: The stock has surged 26.19% over the past month, decisively breaking out from its March lows. This powerful momentum, coupled with a low beta of 0.67, indicates the move is driven by company/sector-specific catalysts rather than broad market strength, suggesting a fundamental re-rating.
- Attractive Valuation Multiples: ELV trades at a trailing P/E of 13.73x and a forward P/E of 13.43x, which is near the bottom of its historical range. Its P/S ratio of 0.39 and EV/Sales of 0.40 represent a significant discount to typical growth stock valuations, offering a margin of safety.
- Regulatory Tailwind from CMS: Recent news confirms a larger-than-expected 2027 Medicare Advantage payment increase from CMS. This directly boosts revenue visibility for Elevance's substantial government-sponsored business, alleviating a key overhang that had pressured the stock earlier in the year.
- Robust Financial Health: The company maintains a strong balance sheet with a debt-to-equity ratio of 0.76 and a current ratio of 1.24. It generated $3.17 billion in TTM free cash flow, providing ample liquidity for dividends, buybacks, and strategic investments without financial strain.
Bearish
- Severe Q4 Profitability Collapse: Q4 2025 net income plummeted to $547 million (net margin of 1.1%) from $2.18 billion in Q1, with gross margin compressing to 23.48% from 27.77%. This extreme quarterly volatility raises questions about earnings quality and sustainability, despite the full-year growth narrative.
- Valuation Discount Reflects Fundamental Risk: The stock's low P/E and P/S multiples are not accidental; they price in significant regulatory uncertainty and margin pressure inherent in the managed care business. The negative PEG ratio of -5.63 signals the market sees no near-term growth premium, questioning the 'value' thesis.
- High Short Interest & Under-Followed Status: A short ratio of 2.86 indicates persistent skepticism among traders. Furthermore, only 3 analysts provide estimates, which is unusually low for a $78B company, suggesting less institutional coverage and potentially less efficient price discovery, increasing volatility risk.
- Recent Rally Nears Key Resistance: The current price of $392.68 is just 5% below the 52-week high of $412.96. After a 26% monthly surge, the stock is at 74% of its yearly range, indicating limited near-term upside before facing significant technical resistance, which could trigger profit-taking.
ELV Technical Analysis
The prevailing price trend for ELV is one of significant volatility within a defined range, culminating in a strong recent recovery. The stock's 1-year price change is a marginal 0.69%, but this masks a dramatic journey; the current price of $392.68 sits at approximately 74% of its 52-week range ($273.71 to $412.96), indicating it has recovered substantially from lows but remains below recent highs, suggesting potential for further mean reversion or a test of resistance. Recent momentum is exceptionally strong and diverges positively from the flat annual trend, with the stock posting a 26.19% gain over the past month and a 13.23% gain over three months, signaling a powerful short-term bullish impulse likely driven by sector-specific catalysts. Key technical levels are clearly defined by the 52-week low of $273.71, which provided a floor during the March sell-off, and the 52-week high of $412.96, which represents the next major resistance; a decisive breakout above $413 would signal a resumption of the prior uptrend, while a breakdown below the recent recovery base near $280 would indicate failure. The stock's beta of 0.67 indicates it is about 33% less volatile than the broader market (SPY), which is notable given its recent sharp moves, suggesting these swings are driven by idiosyncratic, company or sector-specific factors rather than broad market sentiment.
Beta
0.67
0.67x market volatility
Max Drawdown
-37.7%
Largest decline past year
52-Week Range
$274-$413
Price range past year
Annual Return
-2.3%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +22.0% | +4.0% |
| 3m | +14.3% | +8.2% |
| 6m | +24.6% | +11.5% |
| 1y | -2.3% | +24.3% |
| ytd | +11.2% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Elevance's revenue trajectory shows steady growth, with Q4 2025 revenue of $49.75 billion representing a 9.47% year-over-year increase; however, examining the sequential quarterly trend from the income statements reveals revenue peaked in Q3 2025 at $50.71 billion before a slight dip in Q4, indicating potential stabilization or minor seasonal fluctuation rather than a clear acceleration. The company is profitable but with notable margin volatility: Q4 2025 net income was $547 million on a gross margin of 23.48%, but this quarter appears to be an outlier with compressed profitability, as earlier quarters in 2025 showed significantly higher net income (e.g., $2.18 billion in Q1) and gross margins (e.g., 27.77% in Q1), suggesting the full-year picture of expanding margins was interrupted by a weaker Q4. Financial health is robust, supported by a solid balance sheet and strong cash generation; the debt-to-equity ratio is a manageable 0.76, the current ratio is a healthy 1.24 indicating good short-term liquidity, and the company generated substantial free cash flow of $3.17 billion over the trailing twelve months, providing ample internal funding for growth initiatives, dividends, and share repurchases without excessive reliance on debt.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given that Net Income is positive, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 13.73x and a forward PE of 13.43x, with the minimal gap between the two suggesting the market anticipates roughly stable earnings in the near term. Compared to sector averages, Elevance trades at a discount based on its PE multiple; for context, its Price-to-Sales ratio of 0.39 and EV-to-Sales of 0.40 are also exceptionally low, typically indicating the market is assigning a low growth multiple or pricing in significant margin pressures seen in the most recent quarter. Historically, the current trailing PE of 13.73x sits near the bottom of its own historical range observed in the provided data, which has seen peaks above 35x; this positioning at historical lows could signal a value opportunity if the Q4 margin compression proves temporary, but it also reflects the market's current skepticism and pricing of fundamental risks, such as regulatory uncertainty in its government-sponsored plans.
PE
13.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Elevance's primary financial risk is extreme earnings volatility, as demonstrated by net income swinging from $2.18 billion in Q1 2025 to $547 million in Q4—a 75% sequential decline. This margin volatility (gross margin fell from 27.77% to 23.48% over the same period) creates significant forecasting challenges and raises doubts about the sustainability of profitability. While the balance sheet is strong (D/E 0.76), the company's revenue is heavily concentrated in government-sponsored plans, making it highly sensitive to changes in CMS reimbursement rates, which directly drove the recent 37.74% drawdown.
Market & Competitive Risks: The stock trades at a significant discount to historical valuation (P/E of 13.73x vs. past peaks above 35x), but this compression reflects real market fears of regulatory headwinds and competitive pressure in the managed care sector. Its low beta of 0.67 suggests it should be less volatile than the market, yet its recent swings have been dramatic, indicating high idiosyncratic, sector-specific risk. The positive CMS news has provided relief, but the sector remains vulnerable to political rhetoric around healthcare costs and potential future regulatory adjustments that could compress margins anew.
Worst-Case Scenario: The worst-case scenario involves a recurrence of the Q4 2025 margin collapse combined with a future negative regulatory shift from CMS that reduces payment rates below expectations. This could trigger a wave of analyst downgrades and a re-test of the recent panic lows. The realistic downside would be a return to the 52-week low of $273.71, representing a loss of approximately -30% from the current price of $392.68. Given the stock's demonstrated volatility and the high short interest, a break below this level could accelerate selling, potentially pushing the stock down 35-40% in a sustained bear case.
